PharmAthene IncFind Ratings Reports
PHARMATHENE INC's gross profit margin for the second quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. PHARMATHENE INC is extremely liquid. Currently, the Quick Ratio is 7.64 which clearly shows the ability to cover any short-term cash needs. PIP managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 32.25% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY16||Q2 FY15|
|Net Sales ($mil)||2.11||1.15|
|Net Income ($mil)||8.05||-2.34|
|Balance Sheet||Q2 FY16||Q2 FY15|
|Cash & Equiv. ($mil)||23.16||18.41|
|Total Assets ($mil)||27.93||22.62|
|Total Debt ($mil)||0.0||0.25|
|Profitability||Q2 FY16||Q2 FY15|
|Gross Profit Margin||-22.12||-164.66|
|Return on Assets||15.23||-35.97|
|Return on Equity||17.54||-44.36|
|Debt||Q2 FY16||Q2 FY15|
|Share Data||Q2 FY16||Q2 FY15|
|Shares outstanding (mil)||64.79||63.91|
|Div / share||0.0||0.0|
|Book value / share||0.37||0.29|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||273984.0||215461.0|
HOLD. PHARMATHENE INC's P/E ratio indicates a discount compared to an average of 43.43 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 25.30. To use another comparison, its price-to-book ratio of 6.89 indicates a significant premium versus the S&P 500 average of 2.83 and a significant discount versus the industry average of 10.44. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, PHARMATHENE INC proves to trade at a discount to investment alternatives within the industry.
|PIP 43.00||Peers 43.43||PIP 41.69||Peers 21.06|
Average. An average P/E ratio can signify an industry neutral price for a stock and an average growth expectation.
PIP is trading at a valuation on par with its peers.
Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
PIP is trading at a significant premium to its peers.
|PIP NA||Peers 29.93||PIP NA||Peers 0.49|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|PIP 6.89||Peers 10.44||PIP 142.85||Peers 0.31|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
PIP is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
PIP is expected to have an earnings growth rate that significantly exceeds its peers.
|PIP 30.17||Peers 555.79||PIP -49.67||Peers 52.64|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
PIP is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
PIP significantly trails its peers on the basis of sales growth